PE20141120A1 - Compuestos heterociclicos - Google Patents

Compuestos heterociclicos

Info

Publication number
PE20141120A1
PE20141120A1 PE2014000466A PE2014000466A PE20141120A1 PE 20141120 A1 PE20141120 A1 PE 20141120A1 PE 2014000466 A PE2014000466 A PE 2014000466A PE 2014000466 A PE2014000466 A PE 2014000466A PE 20141120 A1 PE20141120 A1 PE 20141120A1
Authority
PE
Peru
Prior art keywords
optionally replaced
compounds
hydroxipiperidin
bipyridin
methanone
Prior art date
Application number
PE2014000466A
Other languages
English (en)
Inventor
Tatsuki Koike
Masato Yoshikawa
Haruhi Ando
William John Farnaby
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47143241&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20141120(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of PE20141120A1 publication Critical patent/PE20141120A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08Bridged systems

Abstract

SE REFIERE A COMPUESTOS DERIVADOS DE 1-ARILCARBONIL-4-OXI-PIPERIDINA DE FORMULA (I) DONDE R1 ES ALQUILO(C1-C6) OPCIONALMENTE SUSTITUIDO; R2 ES H O ALQUILO(C1-C6) OPCIONALMENTE SUSTITUIDO; R3 ES UN HETEROCICLICO AROMATICO DE 5 O 6 MIEMBROS OPCIONALMENTE SUSTITUIDO; EL ANILLO A ES PIPERIDINA OPCIONALMENTE SUSTITUIDO; B ES UN ANILLO AROMATICO DE 5 O 6 MIEMBROS OPCIONALMENTE SUSTITUIDO; X E Y SON CADA UNO C O N. SON COMPUESTOS PREFERIDOS: (4-BENCIL-4-HIDROXIPIPERIDIN-1-IL)(2,4'-BIPIRIDIN-3-IL)METANONA; 2,4'-BIPIRIDIN-3-IL(4-(4-FLUOROBENCIL)-4-HIDROXIPIPERIDIN-1-IL)METANONA; ENTRE OTROS. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON INHIBIDORES DE LA 24-HIDROXILASA DE COLESTEROL (CH24H) SIENDO UTILES EN EL TRATAMIENTO DE LA ENFERMEDAD DE ALZHEIMER, ENFERMEDAD DE PARKINSON, ESCLEROSIS LATERAL AMIOTROFICA
PE2014000466A 2011-10-07 2012-10-03 Compuestos heterociclicos PE20141120A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2011222741 2011-10-07

Publications (1)

Publication Number Publication Date
PE20141120A1 true PE20141120A1 (es) 2014-09-15

Family

ID=47143241

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2014000466A PE20141120A1 (es) 2011-10-07 2012-10-03 Compuestos heterociclicos

Country Status (41)

Country Link
US (11) US8648079B2 (es)
EP (1) EP2763979B1 (es)
JP (1) JP6117191B2 (es)
KR (1) KR101967497B1 (es)
CN (1) CN103842356B (es)
AP (1) AP2014007606A0 (es)
AR (1) AR088226A1 (es)
AU (1) AU2012321815B2 (es)
BR (2) BR112014007257B1 (es)
CA (1) CA2851087C (es)
CL (1) CL2014000806A1 (es)
CO (1) CO6940432A2 (es)
CR (1) CR20140151A (es)
CY (1) CY1121549T1 (es)
DK (1) DK2763979T3 (es)
DO (1) DOP2014000064A (es)
EA (1) EA025662B1 (es)
EC (1) ECSP14013329A (es)
ES (1) ES2716531T3 (es)
GE (1) GEP201706608B (es)
HR (1) HRP20190491T1 (es)
HU (1) HUE043171T2 (es)
IL (1) IL231678A (es)
LT (1) LT2763979T (es)
MA (1) MA35623B1 (es)
ME (1) ME03372B (es)
MX (1) MX360706B (es)
MY (1) MY176126A (es)
PE (1) PE20141120A1 (es)
PL (1) PL2763979T3 (es)
PT (1) PT2763979T (es)
RS (1) RS58470B1 (es)
SG (1) SG2014010417A (es)
SI (1) SI2763979T1 (es)
TN (1) TN2014000122A1 (es)
TR (1) TR201902788T4 (es)
TW (1) TWI582084B (es)
UA (1) UA115133C2 (es)
UY (1) UY34365A (es)
WO (1) WO2013054822A1 (es)
ZA (1) ZA201402424B (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI582084B (zh) 2011-10-07 2017-05-11 武田藥品工業股份有限公司 雜環化合物
JP6249952B2 (ja) 2012-10-16 2017-12-20 武田薬品工業株式会社 複素環化合物
AP2015008591A0 (en) 2012-12-11 2013-07-31 Takeda Pharmaceutical Heterocyclic compounds
US20160031930A1 (en) 2013-03-13 2016-02-04 Sage Therapeutics, Inc. Neuroactive steroids and methods of use thereof
EP2982666B1 (en) 2013-04-04 2019-08-07 Takeda Pharmaceutical Company Limited Heterocyclic compound
US9624184B2 (en) 2013-04-04 2017-04-18 Takeda Pharmaceutical Company Limited Heterocyclic compound
EP3152198B1 (en) 2014-06-09 2019-02-27 Takeda Pharmaceutical Company Limited Radiolabeled compounds
CN104803922A (zh) * 2015-03-14 2015-07-29 长沙深橙生物科技有限公司 一种嘧啶衍生物的制备方法
CA2991313C (en) 2015-07-06 2023-12-19 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
JP6807322B2 (ja) * 2015-10-16 2021-01-06 武田薬品工業株式会社 複素環化合物の製造方法
GB201604029D0 (en) 2016-03-09 2016-04-20 Ctxt Pty Ltd Compounds
DK3436022T3 (da) 2016-04-01 2022-06-20 Sage Therapeutics Inc Oxysteroler og fremgangsmåder til anvendelse heraf
US10752653B2 (en) 2016-05-06 2020-08-25 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
CN109071440A (zh) * 2016-05-13 2018-12-21 日产化学株式会社 2-乙酰基吡啶化合物的制造方法
JP7149266B2 (ja) 2016-09-30 2022-10-06 セージ セラピューティクス, インコーポレイテッド C7置換オキシステロールおよびnmdaモジュレーターとしての方法
GB201617758D0 (en) * 2016-10-20 2016-12-07 Almac Discovery Limited Pharmaceutical compounds
CN111065394B (zh) * 2017-08-31 2023-03-31 武田药品工业株式会社 中枢神经系统病症的治疗
WO2020027344A1 (en) 2018-08-03 2020-02-06 Takeda Pharmaceutical Company Limited Ch24h inhibitors for mdd use
WO2020059894A1 (en) 2018-09-20 2020-03-26 Takeda Pharmaceutical Company Limited CH24H Inhibitors For Pain Use
JP7189749B2 (ja) 2018-12-04 2022-12-14 株式会社日立産機システム スクリュー圧縮機
TW202110824A (zh) * 2019-05-24 2021-03-16 美商賽吉醫療公司 化合物、組合物及使用方法
CA3203010A1 (en) * 2020-11-25 2022-06-02 Sage Therapeutics, Inc. 4-fluoro-(4-(4-benzyl)piperidin-1-yl)(2-(pyrimidin-4-yl)pyridin-3-yl)methanone derivatives and similar compounds as cyp46a1 inhibitors for the treatment of neurodegenerative disorders
IL309208A (en) 2021-06-11 2024-02-01 Sage Therapeutics Inc Neuroactive steroids for the treatment of Alzheimer's disease

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2175083T3 (es) 1995-03-14 2002-11-16 Praecis Pharm Inc Moduladores de la agregacion de amiloides.
EP1586584A1 (en) 1996-08-27 2005-10-19 Praecis Pharmaceuticals Incorporated Modulators of beta-amyloid peptide aggregation comprising D-amino acids
DE60045005D1 (de) 1999-06-28 2010-11-04 Oklahoma Med Res Found Inhibitoren des memapsin 2 und ihre verwendung
AR035016A1 (es) 1999-08-25 2004-04-14 Takeda Chemical Industries Ltd Composicion de azol promotor de produccion/secrecion de neurotrofina, compuesto prodroga del mismo, composicion farmaceutica que lo comprende y uso del mismo para preparar esta ultima.
CA2407149C (en) 2000-04-28 2010-10-12 Takeda Chemical Industries, Ltd. Melanin-concentrating hormone antagonist
CA2408913A1 (en) 2000-05-16 2001-11-22 Takeda Chemical Industries, Ltd. Melanin-concentrating hormone antagonist
AU2002248432A1 (en) 2001-02-14 2002-08-28 Sankyo Company, Limited Oxazole derivatives, their preparation and their use as cytokine inhibitors
MXPA03009846A (es) 2001-04-27 2004-05-05 Vertex Pharma Derivados de triazol inhibidores de cinasa y usos de los mismos.
US20030195192A1 (en) 2002-04-05 2003-10-16 Fortuna Haviv Nicotinamides having antiangiogenic activity
US20040014744A1 (en) 2002-04-05 2004-01-22 Fortuna Haviv Substituted pyridines having antiangiogenic activity
AU2003288231A1 (en) 2002-12-13 2004-07-09 Bayer Healthcare Ag Cholesterol 24-hydroxylase (cyp46) as therapeutic target for the treatment of alzheimer's disease
DOP2005000039A (es) 2004-03-26 2005-10-31 Aventis Pharma Inc Hidrocloruro de [4-(5-aminometil-2-fluoro-fenil)- piperidin-1-il]-(4-bomo-3-metil-5-propoxi-tiofen-2-il)-metanona como un inhibidor de la triptasa de mastocitos
GT200500375A (es) 2004-12-20 2006-11-28 Derivados de piperidina y su uso como agentes antiinflamatorios
WO2006137465A1 (ja) 2005-06-24 2006-12-28 Shionogi & Co., Ltd. 含窒素複素環誘導体
WO2007062999A2 (en) * 2005-11-30 2007-06-07 F. Hoffmann-La Roche Ag 1,5-substituted indol-2-yl amide derivatives
EP1962886B2 (en) 2005-12-20 2022-02-23 Bristol-Myers Squibb Company Stable protein formulations
EP2051977A2 (en) 2006-07-20 2009-04-29 Amgen Inc. SUBSTITUTED AZOLE AROMATIC HETEROCYCLES AS INHIBITORS OF LLbeta-HSD-1
KR101476472B1 (ko) 2007-03-30 2015-01-05 암브룩스, 인코포레이티드 변형된 fgf-21 폴리펩티드 및 그 용도
WO2008134547A1 (en) * 2007-04-25 2008-11-06 Xenon Pharmaceuticals Inc. Methods of using hydroxycyclohexane and hydroxypiperidine compounds in treating sodium channel-mediated diseases or conditions
WO2008153722A1 (en) 2007-05-22 2008-12-18 The Board Of Regents Of The University Of Texas System Post-translational regulation of catalytic activities of cytochrome p450 46a1 and uses thereof
WO2009117421A2 (en) 2008-03-17 2009-09-24 Kalypsys, Inc. Heterocyclic modulators of gpr119 for treatment of disease
JP5656834B2 (ja) 2008-08-22 2015-01-21 サノフイ 肥満細胞トリプターゼインヒビターとしての[4−(5−アミノメチル−2−フルオロ−フェニル)−ピペリジン−1−イル]−[7−フルオロ−1−(2−メトキシ−エチル)−4−トリフルオロメトキシ−1h−インドール−3−イル]−メタノン
ES2567047T3 (es) 2008-12-23 2016-04-19 Abbvie Inc. Derivados de pirimidina anti-virales
DE102009022896A1 (de) 2009-05-27 2010-12-02 Bayer Schering Pharma Aktiengesellschaft Substituierte Piperidine
DE102009022894A1 (de) 2009-05-27 2010-12-02 Bayer Schering Pharma Aktiengesellschaft Substituierte Piperidine
WO2011058766A1 (en) * 2009-11-16 2011-05-19 Raqualia Pharma Inc. Aryl carboxamide derivatives as ttx-s blockers
JP5316468B2 (ja) 2010-04-09 2013-10-16 株式会社豊田自動織機 リアクトル構造
EP2598483B1 (en) 2010-07-29 2020-07-29 Rigel Pharmaceuticals, Inc. Ampk-activating heterocyclic compounds and methods for using the same
US20140018540A1 (en) 2010-12-14 2014-01-16 Electrophoretics Limited Casein kinase 1delta (ck 1delta) inhibitors
TWI582084B (zh) * 2011-10-07 2017-05-11 武田藥品工業股份有限公司 雜環化合物

Also Published As

Publication number Publication date
EP2763979B1 (en) 2018-12-26
LT2763979T (lt) 2019-03-25
BR122022001219B1 (pt) 2023-03-14
AU2012321815A8 (en) 2014-06-12
US9193709B2 (en) 2015-11-24
JP2014528904A (ja) 2014-10-30
NZ623185A (en) 2016-01-29
IL231678A (en) 2017-03-30
BR112014007257B1 (pt) 2023-04-25
US10144743B2 (en) 2018-12-04
CR20140151A (es) 2014-05-26
WO2013054822A1 (en) 2013-04-18
SI2763979T1 (sl) 2019-04-30
US20190071455A1 (en) 2019-03-07
CA2851087C (en) 2019-09-24
US20160326136A1 (en) 2016-11-10
TN2014000122A1 (en) 2015-07-01
AU2012321815A1 (en) 2014-04-24
ECSP14013329A (es) 2014-05-31
GEP201706608B (en) 2017-01-25
CN103842356A (zh) 2014-06-04
ME03372B (me) 2020-01-20
TWI582084B (zh) 2017-05-11
ZA201402424B (en) 2015-07-29
US20140228373A1 (en) 2014-08-14
EP2763979A1 (en) 2014-08-13
US20200157117A1 (en) 2020-05-21
US8871766B2 (en) 2014-10-28
CL2014000806A1 (es) 2014-09-05
AR088226A1 (es) 2014-05-21
HUE043171T2 (hu) 2019-08-28
US10550129B2 (en) 2020-02-04
CN103842356B (zh) 2017-03-15
PL2763979T3 (pl) 2019-06-28
US20190233436A1 (en) 2019-08-01
IL231678A0 (en) 2014-05-28
TR201902788T4 (tr) 2019-03-21
US11174272B2 (en) 2021-11-16
US8648079B2 (en) 2014-02-11
CY1121549T1 (el) 2020-05-29
EA025662B1 (ru) 2017-01-30
US10717748B2 (en) 2020-07-21
US9440990B2 (en) 2016-09-13
RS58470B1 (sr) 2019-04-30
US8865717B2 (en) 2014-10-21
US20170145031A1 (en) 2017-05-25
KR20140072902A (ko) 2014-06-13
UY34365A (es) 2013-05-31
MY176126A (en) 2020-07-24
DK2763979T3 (en) 2019-04-01
US20140088118A1 (en) 2014-03-27
PT2763979T (pt) 2019-04-12
US20130090341A1 (en) 2013-04-11
SG2014010417A (en) 2014-06-27
MX360706B (es) 2018-11-14
EA201490747A1 (ru) 2014-08-29
US20210206781A1 (en) 2021-07-08
AP2014007606A0 (en) 2014-05-31
DOP2014000064A (es) 2014-07-15
JP6117191B2 (ja) 2017-04-19
KR101967497B1 (ko) 2019-04-09
HRP20190491T1 (hr) 2019-05-03
US20150376205A1 (en) 2015-12-31
TW201329068A (zh) 2013-07-16
US9586930B2 (en) 2017-03-07
MA35623B1 (fr) 2014-11-01
BR112014007257A2 (pt) 2017-03-28
ES2716531T3 (es) 2019-06-13
AU2012321815B2 (en) 2017-03-09
US10273245B2 (en) 2019-04-30
UA115133C2 (uk) 2017-09-25
US20140088146A1 (en) 2014-03-27
MX2014004253A (es) 2014-06-11
CA2851087A1 (en) 2013-04-18
CO6940432A2 (es) 2014-05-09

Similar Documents

Publication Publication Date Title
PE20141120A1 (es) Compuestos heterociclicos
PE20141404A1 (es) Derivados de tieno[3,2-d]pirimidina que tienen actividad inhibidora por las quinasas de las proteinas
PE20160844A1 (es) Compuestos triciclicos como agentes anticancerigenos
PE20141203A1 (es) Benzilindazoles sustituidos para uso como inhibidores de la quinasa bub1 en el tratamiento de enfermedades hiperproliferativas
PE20150636A1 (es) Dicianopiridinas alquilamino-sustituidas y sus profarmacos de ester de aminoacido
AR083578A1 (es) INHIBIDORES DE N/N-LACTAMA ACETIL-CoA CARBOXILASA
PE20090773A1 (es) Derivados de morfolina pirimidina
PE20142340A1 (es) Inhibidores de bromodominios
PE20140623A1 (es) Halogenoalquil-1,3-oxazinas como inhibidores de la bace1 y/o bace2
PE20110547A1 (es) Compuestos de isoindolina con actividad anticancerigena
PE20141075A1 (es) 4-aril-n-fenil-1,3,5-triazin-2-aminas que contienen un grupo sulfoximina
PE20120690A1 (es) Derivados de 5-fluoropirimidinona
PE20141005A1 (es) 1,3-oxazinas como inhibidores de bace1 y/o bace2
PE20140397A1 (es) Derivados de fluoro-piridinona utiles como agentes antibacterianos
UY32547A (es) Piperidinas sustituidas como antagonistas de ccr3
DK2091948T3 (da) Nye inhibitorer af glutaminylcyclase
PE20140865A1 (es) Inhibidores de la tirosina-quinasa de bruton
PE20090775A1 (es) Nuevos derivados de biarilo
PE20141004A1 (es) 1,3-oxazinas como inhibidores de la bace1 y/o de la bace2
PE20110136A1 (es) Compuestos organicos
PE20090890A1 (es) Compuestos derivados de 1-(2,3-dihidrobenzo[1,4]dioxin-2-ilmetil)azaciclos como antagonistas del suptipo adrenoreceptor alfa2c
PE20140192A1 (es) Derivados de bencimidazol como inhibidores de cinasa pi3
AR084011A1 (es) Compuestos nitrogenados heterociclicos utiles para el tratamiento de infecciones por el virus sincitial respiratorio (rsv), proceso para prepararlos y composiciones farmaceuticas que los contienen
PE20110196A1 (es) 5-alquinil-pirimidinas
PE20140609A1 (es) Diazacarbazoles y metodos de uso

Legal Events

Date Code Title Description
FG Grant, registration